{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:25:30Z","timestamp":1789133130911,"version":"build-2803163510"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This post hoc analysis of international phase III isavuconazole trials identified 50 patients (90% immunocompromised or diabetic) with invasive fungal sinusitis (88% mucormycetes, Aspergillus) who received isavuconazole as primary (n = 33) or salvage (n = 17) therapy for a median of 82 days (range, 2\u2013882). Overall survival was 82% at day 42 and 70% at day 84.<\/jats:p>","DOI":"10.1093\/cid\/ciab386","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T20:22:36Z","timestamp":1619468556000},"page":"e1380-e1383","source":"Crossref","is-referenced-by-count":14,"title":["Isavuconazole Treatment of Invasive Fungal Sinusitis: A Post Hoc Analysis of the SECURE and VITAL Trials"],"prefix":"10.1093","volume":"73","author":[{"given":"Marlene L","family":"Durand","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese M","family":"Kitt","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Northbrook, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Song","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Northbrook, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3708-8734","authenticated-orcid":false,"given":"Francisco M","family":"Marty","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"key":"2021091515524607700_CIT0001","first-page":"2324709618770473","article-title":"Granulomatous invasive Aspergillus flavus infection involving the nasal sinuses and brain","volume":"6","author":"Jariwal","year":"2018","journal-title":"J Investig Med High Impact Case Rep"},{"key":"2021091515524607700_CIT0002","first-page":"e9610","article-title":"An aggressive case of mucormycosis","volume":"12","author":"Tran","year":"2020","journal-title":"Cureus"},{"key":"2021091515524607700_CIT0003","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.amjoto.2015.12.003","article-title":"Successful isavuconazole therapy in a patient with acute invasive fungal rhinosinusitis and acquired immune deficiency syndrome","volume":"37","author":"Ahmed","year":"2016","journal-title":"Am J Otolaryngol"},{"key":"2021091515524607700_CIT0004","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s15010-013-0552-6","article-title":"Successful isavuconazole salvage therapy in a patient with invasive mucormycosis","volume":"42","author":"Ervens","year":"2014","journal-title":"Infection"},{"key":"2021091515524607700_CIT0005","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2021091515524607700_CIT0006","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2021091515524607700_CIT0007","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) consensus group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2021091515524607700_CIT0008","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/lary.23912","article-title":"Survival outcomes in acute invasive fungal sinusitis: a systematic review and quantitative synthesis of published evidence","volume":"123","author":"Turner","year":"2013","journal-title":"Laryngoscope"},{"key":"2021091515524607700_CIT0009","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2500\/ajra.2015.29.4115","article-title":"Prognostic factors for survival in patients with acute invasive fungal rhinosinusitis","volume":"29","author":"Cho","year":"2015","journal-title":"Am J Rhinol Allergy"},{"key":"2021091515524607700_CIT0010","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/bjophthalmol-2015-306945","article-title":"Invasive fungal disease of the sinus and orbit: a comparison between mucormycosis and Aspergillus","volume":"100","author":"Trief","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"2021091515524607700_CIT0011","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1177\/0194599815627786","article-title":"Acute invasive fungal rhinosinusitis: a 15-year experience with 41 patients","volume":"154","author":"Payne","year":"2016","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2021091515524607700_CIT0012","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/lary.23978","article-title":"Invasive fungal rhinosinusitis: a 15-year experience with 29 patients","volume":"123","author":"Monroe","year":"2013","journal-title":"Laryngoscope"},{"key":"2021091515524607700_CIT0013","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/myc.12884","article-title":"Fungal infections of the central nervous system and paranasal sinuses in onco-haematologic patients: epidemiological study reporting the diagnostic-therapeutic approach and outcome in 89 cases","volume":"62","author":"Candoni","year":"2019","journal-title":"Mycoses"},{"key":"2021091515524607700_CIT0014","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/alr.21714","article-title":"An evaluation of invasive fungal sinusitis outcomes with subsite analysis and use of frozen section analysis","volume":"6","author":"Foshee","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"key":"2021091515524607700_CIT0015","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/alr.22172","article-title":"A multi-institutional review of outcomes in biopsy-proven acute invasive fungal sinusitis","volume":"8","author":"Wandell","year":"2018","journal-title":"Int Forum Allergy Rhinol"},{"key":"2021091515524607700_CIT0016","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1177\/0003489418820871","article-title":"Inpatient mortality after endoscopic sinus surgery for invasive fungal rhinosinusitis","volume":"128","author":"Burton","year":"2019","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"2021091515524607700_CIT0017","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/TP.0b013e3181837585","article-title":"Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant","volume":"86","author":"Alexander","year":"2008","journal-title":"Transplantation"},{"key":"2021091515524607700_CIT0018","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1086\/500212","article-title":"Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases","volume":"42","author":"van Burik","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2021091515524607700_CIT0019","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.50.1.126-133.2006","article-title":"Posaconazole as salvage therapy for zygomycosis","volume":"50","author":"Greenberg","year":"2006","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab386\/38864120\/ciab386.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/6\/e1380\/40392536\/ciab386.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/6\/e1380\/40392536\/ciab386.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T16:24:01Z","timestamp":1631723041000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/6\/e1380\/6259216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":19,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,4,29]]},"published-print":{"date-parts":[[2021,9,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab386","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,15]]},"published":{"date-parts":[[2021,4,29]]}}}